The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback